Ralph A DeFronzo
University of Texas · The University of Texas Health Science Center at San Antonio · The University of Texas Health Science at San Antonio
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
12
all conditions, ClinicalTrials.gov
NIH grants tied to them
10
4 more share only the name and are not shown
Trial papers
109
PubMed author-name match
Trials
Studies that name Ralph A DeFronzo as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:59 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT05838287 · Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus ParticipantsThe University of Texas Health Science Center at San Antonio · recruiting · Type 2 Diabetes Mellitus in Obese, Heart Failure With Preserved Ejection Fraction · principal investigator
- Ph1NCT03560323 · Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1The University of Texas Health Science Center at San Antonio · completed · Heart Failure, Type 2 Diabetes Mellitus · principal investigator
- Ph4NCT03168295 · PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to GlucosuriaThe University of Texas Health Science Center at San Antonio · completed · Diabetes Mellitus, Type 2 · principal investigator
- N/ANCT02969798 · Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)The University of Texas Health Science Center at San Antonio · recruiting · Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG) · principal investigator
- N/ANCT02613897 · ESR-15-11293 - Saxa/Dapa, Safety and Efficacy StudyThe University of Texas Health Science Center at San Antonio · completed · Diabetes Mellitus, Type 2 · study director
- Ph3NCT02592421 · SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2The University of Texas Health Science Center at San Antonio · completed · Type II Diabetes Mellitus · principal investigator
- Ph2NCT02535715 · A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED)The University of Texas Health Science Center at San Antonio · completed · Type 1 Diabetes · principal investigator
- Ph4NCT02299050 · Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue TherapyThe University of Texas Health Science Center at San Antonio · completed · Type 2 Diabetes · principal investigator
- Ph2NCT01972152 · Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe HypoglycemiaXeris Pharmaceuticals · completed · Hypoglycemia · principal investigator
- Ph4NCT01588470 · Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)The University of Texas Health Science Center at San Antonio · completed · Type 2 Diabetes, Coronary Heart Disease · principal investigator
- Ph3NCT00230464 · Acute Metabolic Effects of LAF 237 in Type 2 DiabeticsThe University of Texas Health Science Center at San Antonio · completed · Type 2 Diabetes Mellitus · principal investigator
- Ph3NCT00220961 · Actos Now for Prevention of Diabetes (ACT NOW)The University of Texas Health Science Center at San Antonio · completed · Impaired Glucose Tolerance, Type 2 Diabetes · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 4 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Identification of cell type-specific insulin responsive quantitative trait loci in human skeletal muscleR01DK145103 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · fiscal years 2026 · $707,781 awarded in 2026Same name and institution; not confirmed by an ID
- Ketones, Muscle Metabolism, and SGLT2 InhibitorsR01DK107680 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · fiscal years 2016 to 2026 · $647,334 awarded in 2026Grant number is on one of their registry trials
- SGLT2 Inhibitors, Ketogenesis, and KetoacidosisR01DK024092 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · fiscal years 1986 to 2026 · $674,244 awarded in 2026Grant number is on one of their registry trials
- Targeting hepatic mitochondrial function in humans with NAFLD using insulin sensitizersR01DK129676 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · fiscal years 2022 to 2026 · $682,149 awarded in 2026Same name and institution; not confirmed by an ID
- Discovery of Functional Variants in Type 2 Diabetes Genes in Mexican AmericansU01DK085524 · NIDDK · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · fiscal years 2015 to 2019 · $322,775 awarded in 2019Same name and institution; not confirmed by an ID
- Durability of Early Combination Therapy vs Conventional Therapy in New Onset T2DMR01DK103841 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · fiscal years 2015 to 2017 · $488,805 awarded in 2017Same name and institution; not confirmed by an ID
- SGLT2 INHIBITION AND STIMULATIION OF ENDOGENOUS GLUCOSE PRODUCTIONI01CX001389 · VA · SOUTH TEXAS VETERANS HEALTH CARE SYSTEM · fiscal years 2016Same name and institution; not confirmed by an ID
- Improved Hypoglycemia Rescue DeviceR44DK085809 · NIDDK · XERIS PHARMACEUTICALS, INC. · fiscal years 2011 to 2012 · $576,491 awarded in 2012Grant number is on one of their registry trials
- MECHANISM OF INSULIN SENSITIZING EFFECT OF PIOGLITAZONE-ROLE OF ADIPONECTINM01RR001346 · NCRR · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · fiscal years 1990 to 2008 · $2,923 awarded in 2008Same name and institution; not confirmed by an ID
- Regulation of Hepatic and Peripheral Glucose MetabolismR56DK024092 · NIDDK · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · fiscal years 2005 · $73,000 awarded in 2005Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:59 UTC. The ranking covers the 200 most relevant of 109 PubMed records, and a shared surname and initials can bring in a namesake. All 109 on PubMed
- Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.Diabetes Care · 20051,185 citationsRCR 29.3
- Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.N Engl J Med · 19951,013 citationsRCR 28.6
- 892 citationsRCR 32.8
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.J Clin Invest · 2014671 citationsRCR 22.5
- Pioglitazone for diabetes prevention in impaired glucose tolerance.N Engl J Med · 2011565 citationsRCR 15.3
- Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.J Clin Endocrinol Metab · 1996375 citationsRCR 9.5
- The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone.Diabetes Care · 2009339 citationsRCR 9.6
- Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.Diabetes Care · 2001322 citationsRCR 7.7
- Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.Curr Med Res Opin · 2008314 citationsRCR 8.3
- The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies.Diabetes Care · 2016267 citationsRCR 10.1